BofA analyst Michael Cherny maintains a Buy rating on AmerisourceBergen after the DOJ filed a civil complaint alleging the company failed to disclose suspicious opioid and other controlled substance orders. The news is "not something that would/should create another meaningful overhang" given that an additional lawsuit on the opioid front "isn’t overly surprising," it is part of an ongoing process and the company, based on its response, is "fighting heavily," Cherny tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABC:
- The Justice Department Sues AmerisourceBergen (NYSE:ABC). Here’s Why
- Justice Department files civil complaint against AmerisourceBergen over opioids
- AmerisourceBergen sued by U.S. over ‘suspicious’ opioid orders, Bloomberg says
- Fly Insider: Terns, Air Transport among week’s notable insider trades
- Walgreens (NASDAQ:WBA) Offloads $1 Billion AmerisourceBergen Shares